IP Library Granted Patent US 11,083,881
Granted Patent B2
US 11,083,881 · App. 16/422,195 · Granted Aug 10, 2021

Method for increasing permeability of a cellular layer of epithelial cells

Inventor: Russell Frederick Ross (Jacksonville Beach, FL)
Assignee: SORRENTO THERAPEUTICS, INC.
A61M37/0015A61K9/0021A61K38/1793A61N1/306A61M2037/003A61M2037/0007A61M2037/0023A61M2037/0053A61M2037/0061A61M2205/0244
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,083,881
App. No.
16/422,195
Granted
Aug 10, 2021
Kind
B2
Abstract

A method for increasing permeability of a cellular layer of epithelial cells includes contacting the cellular layer with a nanostructured surface including a plurality of first nanostructures arranged thereon and projecting outward therefrom. A fractal dimension of the plurality of nanostructures is greater than 1. The permeability of the cellular layer by a compound is increased as compared to the permeability of the cellular layer prior to contact with the surface.

Claims (16)

1. A method for increasing permeability of a cellular layer of epithelial cells, the method comprising contacting the cellular layer with a nanostructured surface comprising a microneedle assembly including a plurality of microneedles and a plurality of nanostructures located on each microneedle of the plurality of microneedles, a fractal dimension of the plurality of nanostructures being greater than 1, wherein at least some of the nanostructures of the plurality of nanostructures have a height from about 10 nanometers to about 1 micrometer, and an aspect ratio from about 0.2 to about 5, and wherein the permeability of the cellular layer by a compound is increased as compared to the permeability of the cellular layer prior to contact with the surface.

2. The method according to claim 1 , wherein a transepithelial electrical resistance of the cellular layer is reduced to less than 95% of the transepithelial electrical resistance of the cellular layer prior to contact with the surface.

3. The method according to claim 1 , wherein at least a portion of the nanostructures have a cross-sectional dimension of less than 500 nanometers and greater than 5 nanometers.

4. The method according to claim 1 , wherein the nanostructured surface further comprises microstructures, the plurality of nanostructures including first nanostructures having a cross-sectional dimension smaller than the microstructures.

5. The method according to claim 4 , further comprising second nanostructures having a cross-sectional dimension less than the cross-sectional dimension of the microstructures and greater than the cross-sectional dimension of the first nanostructures.

6. The method according to claim 1 , further comprising a film overlaying at least one microneedle of the microneedle assembly, the film having a first surface and a second surface, wherein the first surface of the film is adhered to the microneedle and at least partially conforms thereto, and wherein the second surface comprises the plurality of nanostructures, wherein the microneedle assembly and the film define a composite microneedle array.

7. The method according to claim 1 , wherein at least one of the microneedles contains a channel along a length of the microneedle, and wherein the compound is configured to flow through the channel.

8. A method for increasing permeability of a cellular layer of epithelial cells, the method comprising:

contacting the cellular layer with a nanostructured surface comprising a microneedle assembly including a plurality of microneedles and a plurality of nanostructures located on each microneedle of the plurality of microneedles, a fractal dimension of the plurality of nanostructures being greater than 1, wherein at least some of the nanostructures of the plurality of nanostructures have a height from about 10 nanometers to about 1 micrometer, and an aspect ratio from about 0.2 to about 5, and, wherein

the permeability of the cellular layer to a compound having a molecular weight of greater than 400 Da is increased at least one-fold as compared to the permeability of the cellular layer prior to contact with the surface.

9. The method according to claim 8 , wherein the fractal dimension of the plurality of nanostructures is about 2.5.

10. The method according to claim 8 , wherein, subsequent to contact between the cellular layer of epithelial cells and the nanostructured surface, a transepithelial electrical resistance of the cellular layer is less than 85% of the transepithelial electrical resistance of the cellular layer prior to contact with the surface.

11. The method according to claim 8 , wherein the interaction of the cellular layer and the nanostructured surface results in at least one of up-regulation of one or more anti- inflammatory cytokines and down-regulation of one or more pro-inflammatory cytokines.

12. The method according to claim 8 , wherein the compound is a selected from a protein therapeutic and a polynucleotide.

13. The method according to claim 8 , wherein the method for increasing the permeability of a layer of epithelial cells changes intercellular junction.

14. The method according to claim 13 , wherein the intercellular junction is a tight junction.

Assignments (6)
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2019
From: ROSS, RUSSELL FREDERICK
To: KIMBERLY-CLARK WORLDWIDE, INC.
Reel/Frame 049279/0305 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 24, 2019
From: KIMBERLY-CLARK WORLDWIDE, INC.
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 049279/0465 →
Continuity (6)
Continuation 15413475 · Jan 24, 2017
Continuation 13641500
Provisional Application 61435963 · Jan 25, 2011
Provisional Application 61411085 · Nov 8, 2010
Provisional Application 61328723 · Apr 28, 2010
Related Publication 20190275310A1 · Sep 12, 2019